Evidence map›Paper›PMID 36467355›Full record

ArticleAnnals of translational medicine2022

Classical

Xiaoqian Zhai, Yanyang Liu, Zuoyu Liang, Weiya Wang, Tian Qin, Stephen V Liu, Sang-Won Um, Feng Luo, Jiewei Liu

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Xiaoqian Zhai *Lung Cancer Center & Institute, West China Hospital, Sichuan University, Chengdu, China.
Yanyang Liu *Lung Cancer Center & Institute, West China Hospital, Sichuan University, Chengdu, China.
Zuoyu LiangPathology Department, West China Hospital, Sichuan University, Chengdu, China.
Weiya WangPathology Department, West China Hospital, Sichuan University, Chengdu, China.
Tian QinBurning Rock Biotech, Guangzhou, China.
Stephen V LiuDepartment of Medicine, Georgetown University, Washington, DC, USA.
Sang-Won UmDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Feng LuoLung Cancer Center & Institute, West China Hospital, Sichuan University, Chengdu, China.
Jiewei LiuLung Cancer Center & Institute, West China Hospital, Sichuan University, Chengdu, China.
Sichuan University · CNWest China Hospital of Sichuan University · CNBurning Rock Biotech (China) · CNGeorgetown University · USSamsung Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anaplastic lymphoma kinase ( Case Description: A 55-year-old male, with no history of smoking history and no family history of cancer, was found malignant pleural effusion and multiple metastasis nodules in the left lung. He was histopathologically diagnosed with Conclusions: Distinct

Indexed as

ALK G1202R mutationcase reportLOC388942-ALKlung cancerresistance mechanism

Identifiers

PMID36467355
PMCPMC9708479
OpenAlexW4309027512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.